Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.39 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14206511 | 0.85 | PARP10 (0.37) | PARP10PARP15ALDH1A1LMNAKDM4E | |
| SCHEMBL18901500 | 0.82 | ALDH1A1 (0.35) | ALDH1A1LMNAKDM4EPKM | |
| SCHEMBL755989 | 0.82 | KDM4E (0.46) | KDM4EPKM | |
| SCHEMBL13447432 | 0.82 | ALOX5 (0.35) | PARP10ALDH1A1LMNAKDM4EPKM | |
| SCHEMBL13388082 | 0.81 | KDM4E (0.33) | ALDH1A1LMNAKDM4EPKM | |
| SCHEMBL13379440 | 0.78 | KDM4E (0.32) | KDM4EPKM | |
| SCHEMBL535693 | 0.78 | L3MBTL1 (0.47) | — | |
| SCHEMBL13412502 | 0.78 | ALDH1A1 (0.38) | PARP10PARP15ALDH1A1LMNAKDM4E | |
| SCHEMBL13485367 | 0.74 | — | — | |
| SCHEMBL3114383 | 0.71 | KDM4E (0.42) | ALDH1A1LMNAKDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024256438-A1 | FUNGICIDAL COMPOSITIONS | SYNGENTA CROP PROTECTION AG (CH) | 2024-12-19 | — | — | WO | disclosed |
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240000767-A1 | COMBINATION OF AN ALPHA2-ADRENOCEPTOR SUBTYPE C (ALPHA-2C) ANTAGONIST WITH A TASK1/3 CHANNEL BLOCKER FOR THE TREATMENT OF SLEEP APNEA | ADRA2C, ADRB2, CHRNA2 | PARP10 3145/4885PARP15 3287/4885ALDH1A1 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.